Hisamitsu Pharmaceutical has been granted a patent for a method to treat osteoarthritis using a patch containing diclofenac sodium, dimethyl sulfoxide, and organic acids. The patch is applied once a day with a dose of 70 mg to 150 mg of diclofenac sodium. GlobalData’s report on Hisamitsu Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hisamitsu Pharmaceutical Co Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hisamitsu Pharmaceutical, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Hisamitsu Pharmaceutical's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11872320B2) discloses a method for treating osteoarthritis through the administration of a patch to a patient. The patch consists of a backing layer and an adhesive layer containing diclofenac sodium, dimethyl sulfoxide, and organic acids. The organic acid content in the adhesive layer ranges from 6% to 8% of the total mass. The patch is applied once a day to the affected area, with a dose of diclofenac sodium between 70 mg to 150 mg per administration. The adhesive base of the patch includes styrene-isoprene-styrene block copolymer and polyisobutylene, releasing 13 mg to 16 mg of diclofenac during a single dose at a rate of 8.6% to 10.7%.

Furthermore, the patent includes variations in the patch composition, such as different adhesive bases like alicyclic saturated hydrocarbon resin and hydrogenated rosin glycerin ester or liquid paraffin. The patch size ranges from 70 cm2 to 140 cm2, with an adhesive mass of 190 g/m2 to 240 g/m2. Specific details regarding the treatment of knee osteoarthritis are provided, including the application of the patch to the inner and outer sides of the knee alternately each day. The patch demonstrates various pharmacokinetic parameters, such as maximum plasma concentration, area under the drug concentration-time curve, and half-life of diclofenac, during both single doses and repeated daily administrations to reach a steady state. The organic acids in the patch, oleic acid, and citric acid, are present in specific proportions to enhance the therapeutic effects of the treatment method.

To know more about GlobalData’s detailed insights on Hisamitsu Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies